Loading...
Loading...
Abiomed
ABMD,
a leading provider of breakthrough heart support technologies, today announced
that the Netherlands has approved new reimbursement coding and payment for the
Impella product. The new coding allows for hospitals to receive funding for
the use of the Impella technology in a broad set of clinical indications of
heart disease through the process known as Diagnosis Treatment Combinations
(Diagnose Behandeling Combinaties; DBCs), similar to the Medicare
Diagnosis-Related Group (DRG) system in the United States.
New reimbursement is a significant milestone for the recognition of Impella as
a required therapy for treatment of heart disease in the European hospital
setting. The Netherlands has also been a leader in early clinical and cost
effectiveness research of the Impella technology under the leadership of Dr.
Jose Henriques at the Amsterdam Medical Center.
"We are encouraged that the Netherlands now provides reimbursement for
Impella," said Michael R. Minogue, Chairman, President and Chief Executive
Officer of Abiomed. "The World Health Organization ranks the Netherlands as
one of the top healthcare systems globally, based upon measurements of the
overall level and distribution of health, responsiveness, and financial
contribution to healthcare services."
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted In: News
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in